from Reuters: Health News https://ift.tt/2IO75SP
Roche immunotherapy combination increases lung cancer survival - study
(Reuters) - Roche's immunotherapy Tecentriq, given with its older drug Avastin and chemotherapy, improved survival of advanced lung cancer patients by about 30 percent over the combination without Tecentriq, according to interim results of a late stage trial released on Wednesday.
from Reuters: Health News https://ift.tt/2IO75SP
from Reuters: Health News https://ift.tt/2IO75SP
Subscribe to:
Post Comments (Atom)
-
The German cabinet will hold a secret session on Wednesday to discuss safeguard measures regarding the possible participation of China's...
-
Stocks poised for another day of gains Equity markets look to add to the gains from the prior session as investor concerns about the fu...
-
By LIAM STACK from NYT Magazine https://ift.tt/2FNPp6k
No comments:
Post a Comment